Comparative Pharmacology
Head-to-head clinical analysis: ANGIO CONRAY versus GADAVIST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANGIO CONRAY versus GADAVIST.
ANGIO-CONRAY vs GADAVIST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angio-Conray (iothalamate meglumine) is a radiopaque contrast agent that attenuates X-rays, providing vascular opacification for angiographic procedures.
Gadovist (gadobutrol) is a macrocyclic gadolinium-based contrast agent (GBCA) that enhances MRI signal intensity by shortening T1 relaxation time in tissues with altered vascularity or blood-brain barrier integrity.
Intravenous: 0.5-1 mL/kg (maximum 100 mL) of a 60% solution for computed tomography; intra-arterial: varies by procedure, typically 5-80 mL of 60% or 76% solution.
0.1 mmol/kg (0.2 mL/kg) IV bolus; maximum dose 0.3 mmol/kg per imaging session.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours; prolonged in renal impairment.
Plasma terminal elimination half-life is approximately 1.5 hours in patients with normal renal function (GFR >60 mL/min/1.73m²). In renal impairment (GFR <30 mL/min/1.73m²), half-life extends to 10-15 hours; in end-stage renal disease, half-life may exceed 30 hours, necessitating adjustment of imaging timing.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Primarily renal; approximately 95% of administered dose excreted unchanged in urine within 72 hours, with 85% eliminated within 6 hours. Less than 1% excreted in feces.
Category C
Category C
Contrast Agent
Contrast Agent